NCT06201507 2024-01-12
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
Phase 2 Unknown
Clinical Trials
11 trialsNCT06186986 2024-01-02
CD30 Imaging in Diffuse Large B-cell Lymphoma
University Medical Center Groningen
Phase 3 Unknown
NCT02098512 2022-10-27
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
New York Medical College
Phase 1/2 Unknown
NCT05006664 2021-09-01
Brentuximab Vedotin in Combination With CHEP in Patient With PTCL
Czech Lymphoma Study Group
Phase 2 Unknown
NCT03474133 2020-07-21
BASALT
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2 Unknown
NCT01476410 2020-02-17
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Northwestern University
Phase 2 Unknown
NCT03527628 2019-11-18
(Optimist)
King Abdullah International Medical Research Center
Phase 2 Unknown
NCT03440788 2019-10-28
Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin
Multinational Center for Quality of Life Research, Russia
Unknown
NCT03540849 2018-05-30
BV-ALLO
University Hospital, Caen
Phase 2 Unknown
NCT02280993 2018-03-13
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1 Unknown
NCT02275598 2014-10-27
Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma
University of Modena and Reggio Emilia
Phase 2 Unknown